Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I) Reviewed by Momizat on . In August 2016, Pfizer announced it would acquire Medivation for $14 billion.  The transaction made headlines for how the size of the deal escalated over a peri In August 2016, Pfizer announced it would acquire Medivation for $14 billion.  The transaction made headlines for how the size of the deal escalated over a peri Rating: 0
You Are Here: Home » QuickPress » Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I)

Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I)

pharma-dealsIn August 2016, Pfizer announced it would acquire Medivation for $14 billion.  The transaction made headlines for how the size of the deal escalated over a period of approximately six months prior to the announcement.  Sujan Rajbhandary, senior member of Mercer Capital’s Financial Reporting Valuation Group, presents in this blog post (and Part II) a broad outline of the transaction and explore what a potential purchase price allocation would look like.

To read the full article in Mercer Capital’s Financial Reporting Blog, click: Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I).

This article is republished from Mercer Capital’s Financial Reporting Blog.  It is reprinted with permission.  To subscribe to the blog, visit: http://mercercapital.com/category/financialreportingblog/.

The National Association of Certified Valuators and Analysts (NACVA) supports the users of business and intangible asset valuation services and financial forensic services, including damages determinations of all kinds and fraud detection and prevention, by training and certifying financial professionals in these disciplines.

Number of Entries : 1528

©2017 NACVA and the Consultants' Training Institute • (800) 677-2009 • 5217 South State Street, Suite 400 Salt Lake City, UT USA 84107

event themes - theme rewards

UA-49898941-1
lw